Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

dabigatran

- PMLiVE

Lilly’s Cyramza not backed in draft NICE guidance

Institute says drug is not a cost-effective use of NHS resources

National Institute for Health and Care Excellence NICE logo

NICE set to recommend seven biologics for severe rheumatoid arthritis

List includes Roche's RoActemra and biosimilars Inflectra and Remsima

- PMLiVE

NICE hands Merck & Co’s Keytruda speedy recommendation

Cancer drug backed for NHS use against advanced melanoma

- PMLiVE

Boehringer Ingelheim appoints Andreas Neumann as HR lead

He will also join the company's board ofmanaging directors

Biosimilars – the same, but different?

As more products reach European markets, US regulations are catching up with science

- PMLiVE

Cancer Drugs Fund axes 16 treatments after overspending

Medicines from Roche, Celgene, Merck KGaA and Janssen among those dropped

- PMLiVE

NICE turns down Celgene’s Otezla once again

Concludes the drug's cost outweighs its benefit for psoriatic arthritis

Daiichi Sankyo logo

NICE recommends Daiichi Sankyo’s Lixiana for DVT and PE

Institute's final guidance concludes the novel oral anticoagulant is cost effective

- PMLiVE

Boehringer Ingelheim’s John Pugh set for move to Accenture

Will take up London-based role in theconsultants' digital department

Can Cinderella save us?

NICE gets tough on antibiotic prescribers

Watchdog says the threat of antimicrobial resistance must be tackled now

Daiichi Sankyo logo

Daiichi’s new anticoagulant recommended by NICE

Lixiana nears NHS funding approval for certain patients with atrial fibrillation

- PMLiVE

BMS launches Opdivo for lung cancer in UK

Drug to be called ‘Nivolumab BMS’ in the country

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links